The purpose of this study is to evaluate the efficacy of chemotherapy in patients with locally advanced or metastatic pancreatic cancer. Results: the authors found that none of the patients showed a complete response after ... months of chemotherapy. However, about 18.3 percent of the patients exhibited partial responses. After treatment, 42.9 percent of the patients were stable, and progressive diseass were observed in 38.8 percent of the patients. At 6 months of treatment, 46.6 percent exhibited progression-free disease (PFS). The median progression-free survival was 5.9 + 1.5 months. At 1 year post chemotherapy, the overal survival rate was 30.9 percent with a median survival was 11.6 + or - 1.5 months. Gemcitabine-chemotherapy combination treatment was more superior than Gemcitabine alone in increasing the overall survival rate of locally advanced or metastatic pancreatic cancer patients. Conclusion: Chemotherapy treatment in combinantion with Gemcitabine is a better therapy than treatment with Gemcitabine alone in improving the survival rates of patients with locally advanced or metastatic pancreatic cancer.
- Đăng nhập để gửi ý kiến